Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Glioma 3Brain Neoplasms 3Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Astrocytoma 2

Interventions

Temozolomide 17Bevacizumab 10Radiotherapy 9Carmustine 9Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 7Carboplatin 7Sorafenib 6Lapatinib 6Chemotherapy, Adjuvant 62,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 6temsirolimus 5Vorinostat 5Surgical Procedures, Operative 5Sirolimus 5Radiosurgery 5Radiation 5Dexamethasone 5cediranib 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4Cilengitide 4pazopanib 3Thalidomide 3Procarbazine 3Nivolumab 3Neoadjuvant Therapy 3Irinotecan 3Iodine-125 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Brain Neoplasms × IL13-PE38 × Clear all
NCT00880061 2018-07-05

An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
7 enrolled
CNS

Brain Neoplasms, Glioma

NCT00036972 2013-06-26

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00006268 2013-06-24

Immunotoxin Therapy in Treating Patients With Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡